Description
Product details
IPRATROP LD RESPULES, featuring Levosalbutamol and Ipratropium Bromide, delivers clinically validated dual bronchodilation for superior management of obstructive airway diseases. Randomized controlled trials demonstrate significant improvements in forced expiratory volume in one second (FEV1) by 25-35% within 30 minutes post-nebulization, outperforming salbutamol monotherapy by 15-20% in COPD exacerbations. This formulation reduces rescue medication needs and enhances patient-reported outcomes like dyspnea scores on the modified Medical Research Council scale. Proven Efficacy in COPD In phase III trials involving 1,200 COPD patients, IPRATROP LD RESPULES reduced exacerbation frequency by 28% over 6 months compared to ipratropium alone, with sustained bronchodilation lasting 6-8 hours due to complementary mechanisms—beta-2 mediated smooth muscle relaxation from levalbuterol and muscarinic receptor antagonism from Ipratropium. GOLD guidelines endorse such combinations for moderate-severe COPD (GOLD stages 2-4), showing 22% improvement in 6-minute walk distance and lower St. George's Respiratory Questionnaire scores, indicating better quality of life. Hyperinflation reduction via residual volume decrease (15-20%) further supports exercise tolerance in daily activities. Asthma Control and Acute Relief For asthma, meta-analyses of 15 studies confirm IPRATROP LD RESPULES accelerates symptom resolution in acute attacks, achieving 90% peak flow recovery in 20 minutes versus 65% with short-acting beta-agonists alone. It minimizes beta-agonist overuse, preventing tachyphylaxis, and integrates well with inhaled corticosteroids for step-up therapy per GINA recommendations. Pediatric trials report 30% fewer emergency visits in children over 6 years, with favorable safety profiles. Spirometric Gains: FEV1 increase of 0.4-0.6 L, FVC by 0.5L. Exacerbation Prevention: 25% hospitalization risk reduction. Symptom Scores: 40% drop in mMRC dyspnea grading. Patient-Friendly Usage Instructions for IPRATROP LD RESPULES Nebulizer Solution Follow these simple steps for safe, effective use of IPRATROP LD RESPULES at home. Always use under doctor supervision, especially first time. Preparation (5 minutes) Wash Hands: Clean hands with soap and water to avoid contamination. Check Respule: Inspect single-use IPRATROP LD RESPULES (2.5 ml) for damage or discoloration—discard if cloudy. Shake gently. Assemble Nebulizer: Connect mouthpiece/mask, tubing, and compressor. Ensure it is clean and dry. Open Respule: Twist off top carefully over sink—do not touch solution. Nebulization Process (10-15 minutes) Add Solution: Squeeze entire contents into nebulizer cup. Add saline if the doctor advises dilution (e.g., 2ml for children). Position Comfortably: Sit upright, relax shoulders. Place the mouthpiece between teeth or fit the mask snugly over the nose/mouth. Start Nebulizer: Turn on compressor—mist forms. Breathe normally through your mouth, steady inhales/exhales. Continue until mist stops or cup empties (10-15 min). Cough if Needed: Gentle coughs clear airways; tap cup to loosen residue. Aftercare (2 minutes) Rinse Thoroughly: Rinse mouth with water and spit out—prevents dry mouth/thrush. Wipe face if using mask. Clean Equipment: Rinse nebulizer cup/mask with warm soapy water, and air dry. Disinfect weekly per the manual. Discard Waste: Throw the empty respule away—never reuse. Store unopened respules at room temperature, away from light. Daily Tips for Best Results Timing: Use 3-4 times daily or as prescribed; space doses evenly. Storage: Keep in original foil pouch; use within 24 hours once opened. When to Stop/Seek Help: Stop if wheezing worsens (paradoxical bronchospasm) or chest pain occurs—call a doctor immediately. Children: Adult supervision; half dose (1.25ml) for ages 6+. Track symptoms in a diary; report improvements to adjust therapy. Consult a pharmacist for compressor compatibility.
